MENU
+Compare
INBX
Stock ticker: NASDAQ
AS OF
Jul 30 closing price
Price
$22.99
Change
-$1.27 (-5.23%)
Capitalization
332.8M

INBX Inhibrx Biosciences Inc. Forecast, Technical & Fundamental Analysis

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms... Show more

INBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INBX with price predictions
Jul 30, 2025

Aroon Indicator for INBX shows an upward move is likely

INBX's Aroon Indicator triggered a bullish signal on July 30, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator showed a similar pattern. In of the 166 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 50-day moving average for INBX moved above the 200-day moving average on July 14, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for INBX moved out of overbought territory on July 30, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 49 cases where INBX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on July 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on INBX as a result. In of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for INBX turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INBX broke above its upper Bollinger Band on July 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.719) is normal, around the industry mean (17.995). P/E Ratio (0.205) is within average values for comparable stocks, (60.242). INBX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.617). Dividend Yield (0.000) settles around the average of (0.045) among similar stocks. INBX's P/S Ratio (1666.667) is slightly higher than the industry average of (277.745).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INBX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INBX is expected to report earnings to fall 44.64% to -154 cents per share on August 19

Inhibrx Biosciences Inc. INBX Stock Earnings Reports
Q2'25
Est.
$-1.55
Q1'25
Missed
by $1.39
Q4'24
Missed
by $1.65
Q3'24
Missed
by $1.36
Q2'24
Beat
by $127.00
The last earnings report on May 14 showed earnings per share of -279 cents, missing the estimate of -140 cents. With 78.05K shares outstanding, the current market capitalization sits at 332.80M.
A.I. Advisor
published General Information

General Information

a company, which engages in researching and developing biotechnology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11025 N. Torrey Pines Road
Phone
+1 858 795-4220
Employees
172
Web
https://www.inhibrx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DNACF17.50N/A
N/A
Dena Co., Ltd.
HINKF83.09N/A
N/A
Heineken N.V.
PRSEF4.95N/A
N/A
Prosafe SE (Cyprus)
SKSUF17.53N/A
N/A
Sekisui Chemical Co.
GIFX0.05-0.02
-23.38%
Gifa, Inc.

INBX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, INBX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INBX
1D Price
Change %
INBX100%
-5.23%
AXON - INBX
48%
Loosely correlated
+2.73%
AKESF - INBX
45%
Loosely correlated
+2.23%
COGT - INBX
41%
Loosely correlated
-2.62%
SNTI - INBX
39%
Loosely correlated
N/A
ACET - INBX
39%
Loosely correlated
+0.13%
More